technicals, page-2

Yes moiramc a nice subject as well. Potential is here and now and the reason i entered ESI after a spell out.

This reminds me of the turnaround story that was PRR. They had no $$ to take forward their Cvac ovarian cancer treatment. Along came a new director Martin Rogers with the ability to get some exposure for PRR and some funds and here we are today with PRR a 300 mill market cap company about to list on the Nasdaq and starting phs3 trials. I know PRR is a biotech but i see ESI at that stage where a new board has turned it around and given ESI the exposure needed around the globe presenting in the U.S and India recently and Asia. Monash Capital funds secured and ESI is on the path PRR was early stages of a big re rate.

Pop up a PRR 5 year chart and comapare to ESI's. We are back in an uptrend and momentum is coming. The bigger traders will see this start to do bigger moves.